ReviewBioengineering (Basel, Switzerland)2021
Designer Exosomes: Smart Nano-Communication Tools for Translational Medicine.
Review in Bioengineering (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention.Fundamental research · 2025Review
- Surface engineering enhances the therapeutic potential of systemically delivered extracellular vesicles following acute myocardial infarction.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Exploring Cardiac Exosomal RNAs of Acute Myocardial Infarction.Biomedicines · 2024Article
- Engineered exosomes in emerging cell-free therapy.Frontiers in oncology · 2024Review
- Identification of Hub Genes and Immune Infiltration in Coronary Artery Disease: A Risk Prediction Model.Journal of inflammation research · 2024Article
- Therapeutic potentials of stem cell-derived exosomes in cardiovascular diseases.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Extracellular vesicles and their cells of origin: Open issues in autoimmune diseases.Frontiers in immunology · 2023Review
- Plasma-Enabled Smart Nanoexosome Platform as Emerging Immunopathogenesis for Clinical Viral Infection.Pharmaceutics · 2022Review
- The emerging role of exosomes in innate immunity, diagnosis and therapy.Frontiers in immunology · 2022Review
- New insights of engineering plant exosome-like nanovesicles as a nanoplatform for therapeutics and drug delivery.Extracellular vesicles and circulating nucleic acids · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes are the master transporters of genes, RNAs, microRNAs, proteins, and lipids. They have applications in major diseases, including cancer, cardiovascular diseases, neurological disorders, and diabetes mellitus. Delivery of the exosomes to recipient cells is governed by the functional heterogenicity of the tissues. Engineered exosomes are promising tools in tissue regeneration. In addition to their role as intracellular communication cargos, exosomes are increasingly primed as standard biomarkers in the progression of diseases, thereby solving the diagnostic dilemma. Futuristic empowerment of exosomes with OMICS strategy can undoubtedly be a bio-tool in translational medicine. This review discusses the advent transformation of exosomes in regenerative medicine and limitations that are caveats to broader applications in clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.